Although methylation of the RASSF1 gene has been investigated in a large number of clinical studies and has been considered as a potential biomarker for breast cancer progression (Grawenda & O’Neill, 2015), how methylation of RASSF1‐2γ influences disease outcome has not been addressed. Here, RASSF1 is linked to breast carcinoma.